NEW YORK, May 7, 2026, 14:09 (EDT)
- Zoetis dropped roughly 20%, slipping after the company trimmed its 2026 outlook and came up short on Q1 expectations from Wall Street.
- U.S. companion-animal sales fell 11%, exposing a soft patch in what investors once considered a reliably sturdy business.
- Management pointed to a drop in vet visits, sharper pricing pressures, and stiffer competition in the pet medicine market.
Shares of Zoetis Inc. dropped roughly 20% Thursday after the animal-health firm trimmed its full-year guidance, blaming fewer vet visits and weaker demand for premium treatments among U.S. pet owners. In afternoon New York trading, the stock changed hands at $88.44.
Zoetis’s slide catches attention—this company serves as a key signal for the premium pet health sector, which so far has outperformed much of consumer spending. For the first quarter, revenue inched up 3% to $2.262 billion, but when you exclude acquisitions and currency swings—looking at organic operational sales—they came in essentially unchanged.
Investors shrugged. Zoetis came in light, posting adjusted earnings of $1.53 per share—short of the $1.61 analysts surveyed by LSEG had penciled in, Reuters reported. Revenue landed at $2.31 billion. Adjusted earnings strip out things like acquisition expenses and purchase-accounting adjustments.
The company has trimmed its 2026 guidance, now putting adjusted earnings between $6.85 and $7.00 per share, with revenue seen at $9.680 billion to $9.960 billion. Back in February, management’s projection had been higher—$7.00 to $7.10 a share and revenue in a $9.825 billion to $10.025 billion range. Zoetis News
Most of the pressure landed in Zoetis’ U.S. pet segment. U.S. revenue slid 8% to $1.1 billion. Sales of companion-animal products dropped 11%, with the dermatology portfolio and Simparica Trio losing ground to rivals. Convenia and Cerenia felt the squeeze from generics, and Librela—the antibody drug for canine osteoarthritis pain—saw weaker sales.
Chief Executive Kristin Peck acknowledged that the first quarter brought tougher conditions than Zoetis had expected. “Increased price sensitivity” from pet owners is putting on pressure, she said, while competition has ramped up in dermatology and the key parasiticide segment—covering flea, tick, and worm treatments. Zoetis News
Peck told analysts there are “more entrants across more markets,” and according to Reuters, competitors are still pushing aggressive pricing and incentives longer than Zoetis anticipated. The company now plans to step up its direct-to-consumer push and tighten partnerships with veterinarians to help bolster demand. Reuters
Daniel Clark, an analyst at Leerink Partners, flagged that U.S. companion-animal sales missed the mark by a wide margin, blaming stiff competition and price-sensitive customers for the softer appetite for Zoetis products.
Offsets existed, but they fell short for investors. International revenue climbed 17% to $1.1 billion, driven by higher demand in both livestock and companion animals, along with a timing lift from Zoetis’ switch in fiscal-year alignment—an accounting tweak that erased a one-month reporting lag outside the U.S. That adjustment, the company noted, kicked in about $100 million of revenue for the quarter.
Pressure wasn’t limited to just one name—Elanco Animal Health dropped roughly 9%. IDEXX Laboratories, a player in veterinary diagnostics, shed about 1% during the afternoon session.
There’s a chance this guidance reduction isn’t the final word—if clinic traffic remains sluggish or rivals maintain price pressure to grab market share, further cuts could follow. Zoetis cautioned its outlook hinges on a range of variables: competition, product launches, deals, foreign exchange, taxes, and more, all of which could shift.
Zoetis keeps highlighting its pipeline to investors, touting more than a dozen candidates that could each bring in at least $100 million a year. The planned purchase of Neogen’s animal genomics business remains on track for the second half of 2026, according to the company. But on the ground, the immediate question is simpler: Will pet owners return to clinics, and how much are they ready to spend?
